Gastro oesophageal cancer, Secondary cancers, Stomach cancer
Open
Phase 3
This trial is looking at rilvegostomig and trastuzumab deruxtecan for cancer that has spread.
It is for people with:
stomach cancer or
cancer of the area where the stomach joins the food pipe (gastro oesophageal junction)
These people also:
have a large number of proteins on their cancer cells (HER2 positive cancer)
have a large number of cancer cells that have a protein called PD-L1
can’t have surgery to treat their cancer
You pronounce rilvegostomig as ril–veh–gost-oh-mig.
Recruitment start: 15 May 2025
Recruitment end: 28 April 2028
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Marco Gerlinger
AstraZeneca
Last reviewed: 07 Nov 2025
CRUK internal database number: 20103
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
